• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类成瘾者抑郁症的诊断与症状。病程及其与治疗结果的关系。

Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome.

作者信息

Rounsaville B J, Weissman M M, Crits-Christoph K, Wilber C, Kleber H

出版信息

Arch Gen Psychiatry. 1982 Feb;39(2):151-6. doi: 10.1001/archpsyc.1982.04290020021004.

DOI:10.1001/archpsyc.1982.04290020021004
PMID:7065829
Abstract

Evaluations of diagnosis and symptoms of depression were undertaken in 157 opiate addicts at entrance to a multimodality drug treatment program and six months later. While 17% were having an episode of major depression (defined by Research Diagnostic Criteria) and 60% had at least mildly elevated depressive symptoms at entrance to treatment, substantial improvement was noted at the six-month reevaluation, with the rates of major depression and elevated symptoms dropping to 12% and 31%, respectively. Symptomatic improvement, although related to retention in treatment, was not the result of specific antidepressant pharmacotherapy and did not differ across treatment modalities. Starting treatment during a major or minor depressive episode was predictive of poorer outcome in the areas of illicit drug use and psychological symptoms, but unrelated to the areas of occupational functioning, legal problems, and program retention.

摘要

在157名阿片类药物成瘾者进入多模式药物治疗项目时及六个月后,对其抑郁症的诊断和症状进行了评估。在进入治疗时,17%的人患有重度抑郁症发作(根据研究诊断标准定义),60%的人至少有轻度抑郁症状加重,而在六个月的重新评估中发现有显著改善,重度抑郁症和症状加重的比例分别降至12%和31%。症状改善虽然与坚持治疗有关,但并非特定抗抑郁药物治疗的结果,且在不同治疗模式之间没有差异。在重度或轻度抑郁发作期间开始治疗可预测在非法药物使用和心理症状方面的较差结果,但与职业功能、法律问题和项目留存方面无关。

相似文献

1
Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome.阿片类成瘾者抑郁症的诊断与症状。病程及其与治疗结果的关系。
Arch Gen Psychiatry. 1982 Feb;39(2):151-6. doi: 10.1001/archpsyc.1982.04290020021004.
2
[Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification].[戒毒后接受美沙酮或阿片类阻滞剂治疗的阿片类成瘾者的抑郁严重程度及复发频率差异]
Vojnosanit Pregl. 2012 Apr;69(4):326-32. doi: 10.2298/vsp1204326j.
3
Heterogeneity of psychiatric diagnosis in treated opiate addicts.接受治疗的阿片类药物成瘾者的精神疾病诊断异质性。
Arch Gen Psychiatry. 1982 Feb;39(2):161-8. doi: 10.1001/archpsyc.1982.04290020027006.
4
Imipramine as treatment for depression in addicts.丙咪嗪用于治疗成瘾者的抑郁症。
Arch Gen Psychiatry. 1983 Jun;40(6):649-53. doi: 10.1001/archpsyc.1983.04390010059007.
5
Naloxone challenge as a biological predictor of treatment outcome in opiate addicts.纳洛酮激发试验作为阿片类成瘾者治疗结果的生物学预测指标
Am J Drug Alcohol Abuse. 1989;15(4):355-66. doi: 10.3109/00952998908992796.
6
Early treatment time course of depressive symptoms in opiate addicts.
J Nerv Ment Dis. 1991 Apr;179(4):215-21. doi: 10.1097/00005053-199104000-00007.
7
Fluoxetine treatment for dually diagnosed methadone maintained opioid addicts: a pilot study.
J Addict Dis. 1994;13(3):25-32. doi: 10.1300/j069v13n03_03.
8
The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study.阿片类药物成瘾者实现戒断的前因及益处:一项为期2.5年的随访研究。
Am J Drug Alcohol Abuse. 1987;13(3):213-29. doi: 10.3109/00952998709001511.
9
Depressive symptoms during buprenorphine treatment of opioid abusers.
J Subst Abuse Treat. 1990;7(1):51-4. doi: 10.1016/0740-5472(90)90035-o.
10
Antidepressant treatment in methadone maintenance patients.美沙酮维持治疗患者的抗抑郁治疗。
J Addict Dis. 1994;13(3):13-24. doi: 10.1300/j069v13n03_02.

引用本文的文献

1
Pretreatment Quality of Life and Substance Use Among Patients Diagnosed With Head and Neck Cancer.诊断患有头颈部癌症患者的治疗前生活质量和物质使用情况。
Cancer Med. 2024 Nov;13(21):e70399. doi: 10.1002/cam4.70399.
2
Cognitive Dysfunction in the Addictions (CDiA): A Neuron to Neighbourhood Collaborative Research Program on Executive Dysfunction and Functional Outcomes in Outpatients Seeking Treatment for Addiction.成瘾中的认知功能障碍(CDiA):一项关于执行功能障碍和寻求成瘾治疗的门诊患者功能结局的从神经元到社区的合作研究项目。
medRxiv. 2024 Oct 28:2024.08.30.24312806. doi: 10.1101/2024.08.30.24312806.
3
Characteristics of patients undergoing medication-assisted -treatment for opioid use disorder and their interest in Tai Chi practice.
接受药物辅助治疗阿片类药物使用障碍患者的特征及其对练太极的兴趣。
J Opioid Manag. 2023 Jul-Aug;19(4):329-341. doi: 10.5055/jom.2023.0790.
4
Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone.使用长效纳曲酮治疗期间阿片类物质使用障碍患者的个人康复情况。
Heliyon. 2023 Jul 5;9(7):e17516. doi: 10.1016/j.heliyon.2023.e17516. eCollection 2023 Jul.
5
Associations of alcohol and cannabis use with change in posttraumatic stress disorder and depression symptoms over time in recently trauma-exposed individuals.近期遭受创伤的个体中,酒精和大麻使用与创伤后应激障碍及抑郁症状随时间变化的关联。
Psychol Med. 2024 Jan;54(2):338-349. doi: 10.1017/S0033291723001642. Epub 2023 Jun 13.
6
Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder.在长效纳曲酮治疗阿片类物质使用障碍期间,抑郁症状学与药物线索反应性的较小降低相关。
J Clin Psychiatry. 2023 Apr 17;84(3):22br14567. doi: 10.4088/JCP.22br14567.
7
Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.丁丙诺啡作为重度抑郁症和阿片类物质使用障碍的一种治疗方法。
Adv Drug Alcohol Res. 2022;2. doi: 10.3389/adar.2022.10254. Epub 2022 Feb 21.
8
Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.患者对持续使用缓释纳曲酮治疗的体验:一项挪威定性研究。
Addict Sci Clin Pract. 2022 Jul 18;17(1):36. doi: 10.1186/s13722-022-00317-2.
9
Sleep Deficiency and Opioid Use Disorder: Trajectory, Mechanisms, and Interventions.睡眠不足与阿片类药物使用障碍:轨迹、机制和干预措施。
Clin Chest Med. 2022 Jun;43(2):e1-e14. doi: 10.1016/j.ccm.2022.05.001.
10
Opioid Use Disorder, Sleep Deficiency, and Ventilatory Control: Bidirectional Mechanisms and Therapeutic Targets.阿片类药物使用障碍、睡眠不足与通气控制:双向机制与治疗靶点。
Am J Respir Crit Care Med. 2022 Oct 15;206(8):937-949. doi: 10.1164/rccm.202108-2014CI.